Mind the methods of determining minimal important differences: three critical issues to consider

Tahira Devji,1 Alonso Carrasco-Labra,2 Gordon Guyatt1

ABSTRACT

Objective Clinical trialists, meta-analysts, and clinical guideline developers are increasingly using minimal important differences (MIDs) to enhance the interpretability of patient-reported outcome measures (PROMs). Here, we elucidate three critical issues of which MID users should be aware. Improved understanding of MID concepts and awareness of common pitfalls in methodological and reporting will better inform the application of MIDs in clinical research and decision-making.

Methods We conducted a systematic review to inform the development of an inventory of anchor-based MID estimates for PROMs. We searched four electronic databases to identify primary studies empirically calculating an anchor-based MID estimate for any PROM in adolescent or adult populations across all clinical areas. Our findings are based on information from 338 studies reporting 3389 MIDs for 358 PROMs published between 1989 and 2015.

Results We identified three key issues in the MID literature that demand attention. (1) The profusion of terms representing the MID concept adds unnecessary complexity to users’ task in identifying relevant MIDs, requiring meticulous inspection of methodology to ensure estimates offered truly reflect the MID. (2) A multitude of diverse methods for MID estimation that will yield different estimates exist, and whether there are superior options remains unresolved. (3) There are serious issues of incomplete presentation and reporting of key aspects of the design, methodology and results of studies providing anchor-based MIDs, which threatens the optimal use of these estimates for interpretation of intervention effects on PROMs.

Conclusions Although the MID represents a powerful tool for enhancing the interpretability of PROMs, realising its full value will require improved understanding and reporting of its measurement fundamentals.

INTRODUCTION

To judge patients’ response to therapy and inform clinical decision-making, clinicians often rely on patients’ self-assessment of change in health status. A typical question clinicians ask their patients is “Since last week when we started the new treatment, are you feeling better or worse—and if so, to what extent?” Such ‘transition questions’ are single items that are short, simple to administer, easy to interpret and are therefore very appealing to clinicians, patients and other healthcare stakeholders.

Although transition questions represent intuitively valuable patient-reported outcome measures (PROMs), classic measurement theory holds that such single item measures have important limitations relative to multi-item measures: they are less stable, reliable and precise. Well-constructed multi-item instruments are also more sensitive to changes in patients’ health status over time (ie, responsive), are able to measure multidimensional phenomena and provide information regarding individual domains. Thus, in clinical research, questionnaires that include multiple items addressing one or more underlying constructs have proved the most trustworthy approach to measuring aspects of health status, including symptoms, functional status and quality of life.7

With the growing emphasis on patient-centred care, major international health policy and regulatory authorities have recognised the importance of evaluating PROMs in clinical research and, to an increasing extent, in clinical practice.2-5 Despite the proliferation of PROMs used in research and practice, there remain substantial challenges interpreting their results. Users of PROM results—including clinicians, guideline developers and patients—often have no intuitive notion whether an apparent treatment effect is trivial in magnitude, small but important, moderate or large. For instance, if a new pharmacological therapy to treat major depression in adults improves patients’ score on the Beck Depression Inventory by three points relative to control, what are we to conclude about the effectiveness of the new treatment? Is the treatment effect large or is it trivial? To address this problem, researchers developed the concept of the minimal important difference (MID): the smallest change—either positive or negative—in an outcome that patients perceive as important.6

There are two commonly used approaches for determining the MID: distribution-based and anchor-based methods. Distribution-based approaches to determining MIDs are based on statistical characteristics of the study sample. These are three categories of distribution-based measures. Those that involve evaluating change in a PROM in relation to either the probability that this change occurred by chance (paired t-statistic,7 growth curve analysis8), sample variation (effect size—with suggestions that treatment effects including 0.2 and 0.5 are minimally important,9 standardised response mean,10 responsiveness statistic11) or measurement precision (SE of measurement, an SD of 0.5,12 the reliable change index13; online supplementary appendix 1).14

Distribution-based approaches rely solely on the variability in PROM scores and do not reflect the patients’ perspective, severely limiting their usefulness in interpreting results.
In the anchor-based approach, investigators establish an MID by relating a difference in PROM scores to an improvement or deterioration captured by an independent measure (ie, the anchor) that is itself interpretable. One common anchor-based approach to estimate the MID is the use of a transition question. For example, Parker et al calculated the MID for Zung Self-rating Depression Rating Scale (ZDS) as the mean change in ZDS score in patients who reported themselves as ‘slightly better’ to the Health Transition Index (comparison of current health with prior to receiving treatment) of the Short-Form-36 health survey, offering response options of markedly better, slightly better, unchanged, slightly worse and markedly worse. Other independent standards include preference ratings (eg, health states), disease-related outcomes (eg, severity of disease, presence of symptoms), non-disease-related outcomes (eg, job loss, healthcare utilisation), normative population(s) (eg, functional or dysfunctional populations), or prognosis of future events (eg, mortality, hospitalisation).

In the last three decades, the number of published studies providing anchor-based MID estimates for PROMs has grown rapidly (figure 1), and MIDs are increasingly being used in trials, meta-analysis and guidelines to enhance the interpretability of PROMs. According to the Web of Science, the paper that described the first empirically developed MID has been cited over 2500 times; in 2019, 30 years after its publication, it was cited 223 times.

In response to this expanding field, our research group has developed resources facilitating the identification and appraisal of anchor-based MIDs. We have developed an inventory of all published studies empirically estimating MIDs for PROMs, and created a novel instrument to evaluate the credibility—the extent to which the design and conduct of studies measuring MIDs are likely to have protected against misleading estimates—of MIDs.

When summarising MIDs and evaluating their credibility, we encountered challenges and identified opportunities to improve current methodological standards. Given the widespread recognition of the usefulness of the MID, elucidating the most critical issues of which MID users should be aware may be of considerable value. Key stakeholders who may find these insights useful include committees that develop clinical practice guidelines and formularies, set market access and reimbursement policies and make regulatory decisions; as well as trialists, systematic reviewers, clinicians and patients. Improved understanding of MID concepts and awareness of common pitfalls in methodology and reporting will better inform the application of MIDs in clinical research, clinical practice and regulatory policy.

METHODS
The development of our inventory involved a systematic survey to summarise primary studies estimating an anchor-based MID for one or more PROMs in adolescent (≥13 to 17) or adult (≥18) populations across all clinical areas. PROMs of interest included self-reported patient-important outcomes of health-related quality of life, function, symptom severity and psychological distress, and well-being. We included any reported MID estimate irrespective of the participants’ condition or disease, type of intervention used in the study, nature of the anchor and its interpretability, or study design. We systematically searched Medline, Embase, Cumulative Index to Nursing and Health Care, PsychINFO, and the Cochrane Library until October 2018. We also hand-searched relevant review articles and textbooks to capture any studies not identified through electronic searching. After removing duplicates, we independently reviewed titles and abstracts against inclusion criteria. A final set of 587 unique studies were included in the inventory. Each study was given a quality score from 1 to 5 based on a prespecified checklist. Refinement of quality assessment criteria and the final quality score cut-off are described elsewhere. MIDs were extracted from all included studies.

Figure 1   Number of published anchor-based minimal important difference estimation studies from 1989 up to October 2018 during each 3-year stratum.
Allied Health Literature (CINAHL) and PsycINFO for studies published between 1989 and April 2015 (the first empirically derived MID appeared in the medical literature in 1989). We also searched the Patient-Reported Outcome and Quality of Life Instruments Database (PROQOLID) internal library and retrieved additional relevant citations and reviewed reference lists from relevant reviews and eligible studies.

For each estimate in our MID inventory, we have abstracted information pertaining to: the study setting; patient demographics; PROM characteristics; interventions administered in the context of the MID estimation; anchor details (ie, type, construct(s), range of options/categories/values, specific anchor-based method); MID estimate, its associated measure of variability, and direction; details regarding MID determination (eg, number of patients informing the MID estimate, duration of follow (if applicable), threshold on the anchor selected to represent a ‘small but important difference’, analytical (or estimation) approach, correlations between the PROM and anchor).

A previously published protocol and subsequent articles documenting the development of our MID inventory (A Carrasco-Labra, personal communication, 2020) and credibility instrument provide full details of the project’s methods. The MID inventory and credibility instrument can be found here: www.promid.org. At the time of writing, we are in the process of updating our MID inventory to include articles published between April 2015 and October 2018; however, our findings presented herein are based on the first 338 studies reporting 3389 anchor-based MID estimates for 358 PROMs published between 1989 and 2015.

RESULTS

Lack of a consistent nomenclature

In 1987, Guyatt et al introduced the MID concept, labelling the concept the minimal clinically important difference. Because this terminology focused attention on the clinical arena as opposed to patients’ experience, the same group of researchers later suggested dropping the word ‘clinical’, and relabelled the concept as the MID. The authors subsequently asserted that the patients who are providing information on aspects of their health status are in the best position to ultimately judge whether a difference in a PROM is or is not important. Many might consider this semantic distinction important, and the universal adoption might add clarity to the discussion.

In the 338 anchor-based MID studies currently included in our inventory, we identified 86 unique terms referring to the MID concept (online supplementary appendix 2). Most deviations from the original and revised terminology were trivial (eg, minimum clinically important difference), but others were more problematic (eg, clinically relevant change, minimal patient perceivable deterioration, responder definition improvement).

This profusion of terms is often a semantic matter, but sometimes represents a different concept. For instance, MIDs for improvement may sometimes differ from those of deterioration, and thus being explicit about the direction of the difference (or change) may be warranted (eg, minimal important improvement, minimal important deterioration). Further, some researchers suggest the usefulness of distinguishing between methods that rely on within-person changes and those that quantify differences between groups.

Such inconsistencies in terminology add unnecessary complexity to reviewers’ task in comprehensively identifying relevant MIDs, requiring meticulous inspection of methodology in individual studies to ensure estimates offered truly reflect the MID. Thus, to avoid confusion and minimise the risk of MIDs going undetected when searching the literature, effort should be made to standardise terminology, and where appropriate reflect important conceptual distinctions.

Multitude of diverse methods for MID estimation—determining whether the MID actually reflects a small but important difference

Generally speaking, the methodology underpinning an anchor-based MID relies on two key components: (1) the anchor and (2) the analytical (or estimation) approach. The appropriate use of an anchor for MID estimation requires knowledge regarding the magnitude of difference on the anchor that is small but important to patients. Two-thirds of the MIDs in our inventory were estimated using a transition rating—perhaps not surprising given that transition ratings are easily understandable for both clinicians and patients, and can easily be framed to relate closely to the construct that the PROM is measuring. Investigators must, however, choose the right response option to correspond to the MID (eg, ‘a little better’ would be a choice much superior to ‘much better’). Quantifying a change that is small but important to patients on other anchor types such as haemoglobin levels, incontinence episodes or Crohn’s Disease Activity Index are likely to be much more challenging.

Although anchors with a very limited relation to patient function or experience (such as haemoglobin) are very likely poor choices, there is no consensus on the type of anchor that is best suited for ascertaining MIDs. Moreover, for the same anchor, the threshold defining the MID often differs across studies. Applying our credibility instrument to the studies in our inventory revealed that, in our judgement, anchors reflected a small but important difference in only 43% of putative MIDs.

Further complicating matters, even after the threshold is set, there are a multitude of statistical approaches to compute the MID, each with its own merits and limitations. The different analytical methods will yield different estimates, and whether one or more represent better choices remains unresolved. Box 1 presents the different analytical methods identified in the anchor-based MID estimation studies included in our inventory.

The recent Consolidated Standards of Reporting Trials (CONSORT) Patient-Reported Outcome (PRO) Extension addresses the need for enhanced interpretation of PRO results, and encourages authors to include discussion of an MID or a responder definition in clinical trial reports. This demand for increased MID reporting in trials will require clinical trialists and users of trial data to better understand MID methodology and distinguish between more and less trustworthy MID estimates. Failure to use credible MIDs to provide interpretable estimates of treatment effects measured by PROMs may lead to serious misinterpretations of findings from otherwise well-designed clinical trials and meta-analyses. Future research should aim to better understand the strengths and limitations of the various analytical methods used by researchers estimating anchor-based MIDs, and strive towards harmonisation of MID methods that will yield robust estimates.

Inadequate reporting and the need for the development of a reporting standard for better transparency

In addition to appropriate design, conduct and analysis, investigators must also report clear, transparent research methods and findings. In the development of our inventory of MIDs, we found major deficiencies in reporting. The usefulness of the anchor-based approach is critically dependent on the extent
Box 1  Analytical methods reported in the anchor-based minimal important difference (MID) estimation studies included in the MID inventory

1. Changes within patients over time
The MID is the mean change in patient-reported outcome measure (PROM) scores over time within the subgroup of participants who reported a small but important change (ie, improvement and/or worsening).

The MID is the median change in PROM scores over time within the subgroup of participants who reported a small but important change.

The MID is defined as the 75th percentile of the distribution of change in PROM scores within the subgroup of participants who reported a small but important change.

The MID is the lower or upper limit of the 95% CI of the mean change in PROM scores over time within the subgroup of participants who reported a small but important change.

The MID is estimated using a regression model (either logistic or linear), in which the dependent variable is the change in PROM score and the independent variable is the value, rating or category on the anchor that reflects a small but important change. Alternatively, the PROM score at follow-up may be the dependent variable, while the independent variables in this model are the value, rating or category on the anchor and the baseline PROM score. A second approach, although less common, involves using the anchor as a dependent variable and the PROM as the independent variable.

The MID is estimated using an analysis of variance model, in which the dependent variable is the change in PROM score and the independent variable is the value, rating or category on the anchor.

The MID is estimated using discriminant function analysis.

The MID is estimated using linkage (or scale alignment) to estimate the MID.

2. Differences between groups capturing changes within patients over time.
The MID is the mean change in PROM scores over time in the participants with a small but important change minus the mean change in PROM scores over time in the participants with no change. This method attempts to correct for the change in PROM scores in the no change group.

The MID is the change in PROM scores over time in the participants in one group minus the mean change in PROM scores over time in the participants in another group. The participants in these groups have a different status on the same condition or disease-related outcome.

3. Differences between patients’ PROM scores at one timepoint.
The MID is the difference in PROM scores between participants who rated themselves compared with another participant, as a little bit better (or a little bit worse) versus participants who rated themselves, compared with another participant, as about the same.

The MID is the difference in PROM scores between participants in groups with a different status on the same condition or disease-related outcome.

The MID is estimated using a regression model (either logistic or linear), where the dependent variable is the PROM score and to which the PROM and anchor measure the same, similar or related constructs. Thus, perhaps arguably, the single most important aspect of credibility of the MID is the correlation between the PROM and anchor. In our inventory, we found that, for 71% of MIDs, authors did not report an associated correlation coefficient.

Further, our confidence in an MID estimate will be lower if the CI around the point estimate is insufficiently narrow; yet, for 56% of MIDs, authors did not report a measure of precision. Even simpler issues, such as the number of patients informing the MID, proved unclear for 22% of MIDs; a similar number failed to report the range of the patient-reported measurement scale for which the MID was determined. Because different scales often exist for a single PROM, this is problematic. For example, the Western Ontario and McMaster Universities Osteoarthritis Index pain instrument may be rated on a 5-point likert-type scale with items summing to give a possible range of 0–20 or as a 0–100 visual analogue scale. Moreover, in some studies, investigators will transform scores to a different scale (eg, 0–100) than reported by the authors who developed the instrument.

Judging the credibility and applicability of MIDs requires complete and accurate reporting: inadequate reporting in MID determination studies will threaten the optimal use of these estimates for interpretation of intervention effects on PROMs in clinical trials, systematic reviews and clinical practice guidelines. The use of reporting guidelines for other types of research, such as the CONSORT statement for randomised trials, has resulted in improved reporting.59 10 In similar fashion, the development of a reporting guideline for anchor-based MID estimation studies will likely improve the completeness and transparency of MID reports and promote higher methodological standards for robust MID estimation. At the time of writing, our research group is in the initial stages of developing such a standard, and we invite
global experts on MID and PRO methods to collaborate with this initiative.

CONCLUSIONS
Although the MID represents a powerful tool for enhancing the interpretability of PROMs, realising its full value will require improved understanding and reporting of its measurement fundamentals. Some of the issues we have labelled—in particular, terminology and completeness of reporting, are easily addressed. Others, such as choice of optimal anchors and response options representing a small but important threshold difference, and optimal statistical approaches, are likely to prove more challenging. Empirical investigations in the exploration of factors explaining variability in MIDs may aid in informing the desperately needed harmonisation of methods.

Twitter Tahira Devji @TahiraDevji

Acknowledgements The authors thank Anila Qasim, Mark Phillips, Bradley C Johnston, Niveditha Devasenapathy, Dena Zeraatk, Meha Bhatt, Xuejing Jin, Romina Brignardello-Petersen, Olivia Urquhart, Farid Foroutan, Stefan Schandelmaier, Hector Farro-Hernandez, Robin WM Vemosis, Haisaomin Huang, Yamna Rizwan, Reed Siemieniuk, Lyubov Lyubyn, Donald L Patrick, Shani Ebrahim, Toshi Furukawa, Gihad Niesalaiah, Holger J Schummann, Mohit Bhandari, and Lehana Thabane for their contributions on the MID inventory and credibility instrument projects.

Contributors The authors are the lead investigators of a programme of research focused on advancing PRO and MID methods. GG is Distinguished Professor in the Departments of Health, Research Methods, Evidence and Impact (HEI), and Medicine focused on advancing PRO and MID methods. GG is Distinguished Professor in the Departments of Health, Research Methods, Evidence and Impact (HEI), and Medicine focused on advancing PRO and MID methods. GG is Distinguished Professor in the Departments of Health, Research Methods, Evidence and Impact (HEI), and Medicine focused on advancing PRO and MID methods. GG is Distinguished Professor in the Departments of Health, Research Methods, Evidence and Impact (HEI), and Medicine focused on advancing PRO and MID methods.

Funding The projects informing the submitted work were funded by the Canadian Institutes of Health Research, Knowledge Synthesis grant number KRS138214.

Complying interests No, there are no competing interests.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

ORCID ID Tahira Devji http://orcid.org/0000-0001-8414-7410

REFERENCES
1 Bowling A. Just one question: if one question works, why ask several? BMJ Publishing Group Ltd. 2005.
4 Doward LC, Gnanasakthy A, Baker MG. Patient reported outcomes: looking beyond the label claim. Health Qual Life Outcome 2010;8:89.
12 Norman GR, Sloan JA, Wynich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582–92.
25 King MT, Dueck AC, Revicki DA. Can methods developed for interpreting group-level patient-reported outcome data be applied to individual patient management? Med Care 2018;56:538–45.